Methods of treatment with compounds having RARalpha receptor specific or selective activity

摘要

Retinoid compounds which act specifically or selectively on RARalpha receptor subtypes in preference over RARbeta and RARGAMMA receptor subtypes, possess desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.